Microfluidics claimed that the LV1, which operates with the same fixed-geometry interaction chamber technology of larger volume machines, brings better capabilities for uniform particle size reduction and cell disruption to samples as small as 1ml, and that industry and academic research teams are able to achieve superior nanoemulsions, nanosuspensions, nanoencapsulation and protein yield while reducing quantities of limited and expensive materials used.
Michael Ferrara, president and CEO of Microfluidics, said: “Customers have told us that they’ve been waiting for a product like the LV1. By lowering the minimum volume requirements of our gold standard Microfluidizer processors, our engineers have made smaller particles and efficient cell rupture more accessible to innovative research teams. The LV1 is an exclusive alternative for an industry continually seeking to improve product quality and consistency without exhausting their resources.”
The LV1 generates higher levels of shear, up to 12.25 million sec-1, which in terms of size are greater than other technologies, and this increased shear allows biotechnology customers to achieve high cell rupture rates for challenging applications in a fraction of the time, which is not the case with other technologies. Furthermore, media and chemical-free coupling, including effective cooling, considerably improves protein yield and makes each ml of material more valuable.
The heart of every Microfluidizer processor is the fixed-geometry interaction chamber and a constant pressure pumping system, which together ensure the most effective and uniform processing performance.
The company said that the LV1 is a highly efficient processor with a small footprint and quiet operation, despite producing pressures up to 2069 bar (30,000 psi) with low power consumption. In contrast to other technologies, results achieved on the LV1 are scalable through lab, clinical trial and pilot/production volumes.